PCM
TPST icon

Prelude Capital Management’s Tempest Therapeutics TPST Stock Holding History

Prelude Capital Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Hold
0
– -$28K – 2039
2015
Q1 		– Hold
0
– – – 1679

Other funds holding TPST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Prelude Capital Management's TPST Position: Q1 2020 in Review

Prelude Capital Management sold out of Tempest Therapeutics (TPST) in Q1 2020, closing a stake of 5 shares — an estimated $6K sold.

Prelude Capital Management first reported a position in TPST in Q4 2019 and held it in 1 quarter. The position peaked at $6K in Q4 2019. 61 funds tracked by Wall St. Rank hold TPST as of Q1 2020.

  • Prelude Capital Management reported no remaining Tempest Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Prelude Capital Management sold 5 Tempest Therapeutics shares in Q1 2020, an estimated $6K.
  • Prelude Capital Management first reported a position in Tempest Therapeutics in Q4 2019 and held it in 1 quarter.
  • Prelude Capital Management's Tempest Therapeutics position peaked at $6K in Q4 2019.
  • 61 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2020.

Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.